ES1

ES1 is a pentameric form of a novel antibody, AFAI, which recognises a variant of CEACAM6. CEACAM6 is a carcinoembryonic antigen-related cell adhesion molecule which is upregulated in neoplasia. The expression of the variant recognised by AFAI is largely restricted to non-small cell non-squamous carcinoma of the lung. ES1 is not yet commercially available.

Immunohistochemical expression

ES1 shows a predominant membrane distribution, with some cases showing cytoplasmic staining.

 

 

 

ES1

TTF-1

 
 

negative

weak

moderate or strong staining

 
 

<10% of cells

10%-50% of cells

>50% of cells

 

Normal tissues

lung

56/56

 

 

 

 

 

other

46/47

 

1/47

 

 

 

Lung tumours

Adenocarcinoma

 

 

3/22

11/22

8/22

20/22

Undifferentiated non small cell carcinoma

1/6

 

 

3/6

2/6

1/6

Bronchoalveolar carcinoma

 

 

4/7

3/7

 

6/7

Adenosquamous carcinoma

 

 

1/2

1/2

 

0/2

Squamous cell carcinoma

3/5

2/5

 

 

 

0/5

Small cell carcinoma

3/3

 

 

 

 

0/3

Atypical adenomatous hyperplasia

2/6

3/6

1/6

 

 

0/6

Extra-pulmonary mucin-secreting tumours

Carcinoid tumour

3/3

 

 

 

 

0/3

Colonic adenocarcinoma

1/15

3/15

3/15

5/15

3/15

0/15

Breast ductal carcinoma

2/8

1/8

3/8

2/8

 

0/8

Pancreatic adenocarcinoma

1/6

2/6

1/6

2/6

 

0/6

Gastric adenocarcinoma

2/6

1/6

2/6

1/6

 

0/6

Gallbladder adenocarcinoma

 

 

 

1/1

 

0/1

Oesophageal adenocarcinoma

 

1/3

2/3

 

 

0/3

Urinary bladder adenocarcinoma

 

1/2

1/2

 

 

0/2

Ovarian mucinous adenocarcinoma

2/3

 

1/3

 

 

0/3

Tracheal adenoid cystic carcinoma

1/1

 

 

 

 

0/1

Urothelial carcinoma

2/4

1/4

1/4

 

 

0/4

Colonic adenoma

1/4

2/4

1/4

 

 

0/4

Extra-pulmonary non-mucinous tumours

Renal cell carcinoma

3/4

1/4

 

 

 

0/4

Hepatocellular carcinoma

2/5

3/5

 

 

 

0/5

Ovarian serous papillary carcinoma

4/4

 

 

 

 

0/4

Papillary thyroid carcinoma

4/5

1/5

 

 

 

0/5

Salivary pleomorphic adenoma

3/3

 

 

 

 

0/3

Mesothelioma

5/5

 

 

 

 

0/5

Prostatic adenocarcinoma

3/3

 

 

 

 

0/3

Endometrioid carcinoma

2/2

 

 

 

 

0/2

Oesophageal squamous carcinoma

1/1

 

 

 

 

0/1

               

 

Diagnostic utility

Possibly useful in the differentiation of tumours arising from a pulmonary primary from thsoe arising from other sites but there has only been one published study.

References

1 Mai KT, Perkins DG, Zhang J, et al. ES1, a new lung carcinoma antibody- an immunohistochemical study. Histopathology 2006; 49:515-22

This page last revised 14.11.2006.

©SMUHT/PW Bishop